Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.

[1]  S. Novello,et al.  Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  P. Soulié,et al.  Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. Rosell.  Managing poor performance non-small-cell lung cancer patients. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Soria,et al.  Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M H Cullen,et al.  The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Agelaki,et al.  Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report. , 2000, Seminars in oncology.

[7]  A. Gregor,et al.  Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Langer.  The role of new agents in advanced non—small–cell lung carcinoma , 2000, Current oncology reports.

[9]  S. Barni,et al.  Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Raymond,et al.  Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines , 1999, Cancer Chemotherapy and Pharmacology.

[11]  E. Raymond,et al.  Oxaliplatin: a review of preclinical and clinical studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Armand,et al.  Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC) , 1998 .

[13]  M. Marty,et al.  Pharmacokinetics and safety profile of oxaliplatin. , 1998, Seminars in oncology.

[14]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[15]  M. Kris,et al.  New chemotherapeutic agents for non-small cell lung cancer. , 1995, Chest.

[16]  F. Invernizzi,et al.  Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. , 1994, Chest.

[17]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M Lavandier,et al.  Benefits of polychemotherapy in advanced non‐small‐cell bronchogenic carcinoma , 1982, Cancer.

[19]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.